Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma

Web Exclusives - FDA News & Updates, Web Exclusive

On June 16, 2017, the FDA approved daratumumab (Darzalex; Janssen Biotech), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Rev­limid) and a proteasome inhibitor.

“This offers another alternative to patients with multiple myeloma who haven’t seen lasting effects from other types of treatment,” said Jan van de Winkel, PhD, Chief Executive Officer, Genmab.

The approval was based on data from the phase 1 EQUULEUS clinical trial involving 103 patients with multiple myeloma who received previous therapy. Patients received 16 mg/kg of daratumumab plus pomalidomide and dexamethasone until disease progression. The primary efficacy end point was the overall response rate (ORR).

The ORR was 59.2%. The stringent complete response rate was 7.8%, the complete response rate was 5.8%, the very good partial response rate was 28.2%, and the partial response rate was 17.5%.

The most common (≥20%) all-grade adverse reactions in patients who received daratumumab plus pom­alidomide and dexamethasone included infusion reactions, diarrhea, constipation, nausea, vomiting, fatigue, pyrexia, upper respiratory tract infection, muscle spasms, back pain, arthralgia, dizziness, insomnia, cough, and dyspnea. Overall, 49% of patients had serious adverse reactions, and 13% of patients discontinued therapy because of adverse reactions.

Related Items
Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer
Web Exclusives published on August 10, 2017 in FDA News & Updates, Web Exclusive
Blincyto Receives Expanded Indication to Include Patients with Ph+ B-Cell Precursor ALL
Web Exclusives published on August 10, 2017 in FDA News & Updates, Web Exclusive
First FDA-Approved Test to Help Detect Several Leukemias and Lymphomas
Web Exclusives published on August 10, 2017 in FDA News & Updates, Web Exclusive
First CAR T-Cell Therapy Unanimously Recommended by FDA Advisory Committee for Treatment of B-Cell ALL in Children and Young Adults
Web Exclusives published on August 10, 2017 in FDA News & Updates, Web Exclusive
Rituximab Combination Now Approved in 3 Blood Cancers
Web Exclusives published on August 10, 2017 in Web Exclusive
Last modified: August 10, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME